{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:14:50Z","timestamp":1789650890324,"version":"4.0.0"},"reference-count":44,"publisher":"Impact Journals, LLC","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2020,6,8]]},"DOI":"10.18632\/aging.103285","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T20:59:31Z","timestamp":1591649971000},"page":"10663-10675","source":"Crossref","is-referenced-by-count":14,"title":["Association between immune-related adverse events and efficacy of PD-1 inhibitors in Chinese patients with advanced melanoma"],"prefix":"10.18632","volume":"12","author":[{"given":"Jing-Jing","family":"Zhao","sequence":"first","affiliation":[{"name":"Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"},{"name":"Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi-Zhi","family":"Wen","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"},{"name":"Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Ding","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"},{"name":"Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan-Dan","family":"Li","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"},{"name":"Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bao-Yan","family":"Zhu","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"},{"name":"Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"},{"name":"Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Sheng","family":"Weng","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"},{"name":"Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"},{"name":"Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Shi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Sun Yat-Sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China"},{"name":"Department of Biotherapy, Sun Yat-Sen University Cancer Center, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.","volume":"13","author":"Bray","year":"2015","journal-title":"Int J Cancer"},{"key":"2","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1097\/CMR.0000000000000256","article-title":"Safety of immune checkpoint inhibitors in chinese patients with melanoma.","volume":"2","author":"Zhang","year":"2016","journal-title":"Melanoma Res"},{"key":"3","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1200\/JCO.2012.45.5568","article-title":"Targeting oncogenic drivers and the immune system in melanoma.","volume":"3","author":"Ribas","year":"2013","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.","volume":"1","author":"O\u2019Day","year":"2015","journal-title":"Lancet Oncol"},{"key":"5","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.","volume":"2","author":"Hansen","year":"2015","journal-title":"Ann Oncol"},{"key":"6","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.","volume":"37","author":"Wagstaff","year":"2015","journal-title":"N Engl J Med"},{"key":"7","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.","volume":"38","author":"Zarour","year":"2014","journal-title":"Lancet"},{"key":"8","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.1158\/1078-0432.CCR-16-0127","article-title":"Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab.","volume":"2","author":"Heinzerling","year":"2016","journal-title":"Clin Cancer Res"},{"key":"9","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","article-title":"Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions.","volume":"5","author":"Gutzmer","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"10","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.","volume":"36","author":"Patnaik","year":"2013","journal-title":"N Engl J Med"},{"key":"11","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/jamadermatol.2015.2707","article-title":"Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab.","volume":"15","author":"Champiat","year":"2016","journal-title":"JAMA Dermatol"},{"key":"12","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during t-cell checkpoint blockade in patients with non-small-cell lung cancer.","volume":"2","author":"Hellmann","year":"2017","journal-title":"Ann Oncol"},{"key":"13","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression.","volume":"15","author":"Ortiz-Urda","year":"2015","journal-title":"JAMA Dermatol"},{"key":"14","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.","volume":"3","author":"Puzanov","year":"2014","journal-title":"J Clin Oncol"},{"key":"15","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.","volume":"36","author":"Antonia","year":"2012","journal-title":"N Engl J Med"},{"key":"16","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.","volume":"3","author":"Chen","year":"2013","journal-title":"J Clin Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma.","volume":"36","author":"Kronenberg","year":"2013","journal-title":"N Engl J Med"},{"key":"18","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","article-title":"Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study.","volume":"1","author":"Tomii","year":"2017","journal-title":"J Thorac Oncol"},{"key":"19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.","volume":"2","author":"Fran\u00e7ois","year":"2016","journal-title":"Ann Oncol"},{"key":"20","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1158\/2326-6066.CIR-17-0063","article-title":"Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center.","volume":"6","author":"Ledezma","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"21","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.","volume":"2","author":"Wolchok","year":"2015","journal-title":"Ann Oncol"},{"key":"22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors.","volume":"4","author":"Larkin","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"23","doi-asserted-by":"publisher","first-page":"e53745","DOI":"10.1371\/journal.pone.0053745","article-title":"The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network.","volume":"8","author":"Grabbe","year":"2013","journal-title":"PLoS One"},{"key":"24","doi-asserted-by":"publisher","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade.","volume":"1","author":"White","year":"2007","journal-title":"Clin Cancer Res"},{"key":"25","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1158\/1078-0432.CCR-15-1136","article-title":"Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes.","volume":"2","author":"Weber","year":"2016","journal-title":"Clin Cancer Res"},{"key":"26","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.","volume":"3","author":"Luiten","year":"2015","journal-title":"J Clin Oncol"},{"key":"27","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma.","volume":"3","author":"Robert","year":"2017","journal-title":"J Clin Oncol"},{"key":"28","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer.","volume":"4","author":"Nakagawa","year":"2018","journal-title":"JAMA Oncol"},{"key":"29","doi-asserted-by":"publisher","first-page":"e1231292","DOI":"10.1080\/2162402X.2016.1231292","article-title":"Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer.","volume":"5","author":"Flatz","year":"2016","journal-title":"Oncoimmunology"},{"key":"30","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma.","volume":"35","author":"Bastian","year":"2005","journal-title":"N Engl J Med"},{"key":"31","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/path.4204","article-title":"Genome sequencing of mucosal melanomas reveals that they are driven by distinct mechanisms from cutaneous melanoma.","volume":"23","author":"Marais","year":"2013","journal-title":"J Pathol"},{"key":"32","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/pcmr.12279","article-title":"The mutational burden of acral melanoma revealed by whole-genome sequencing and comparative analysis.","volume":"2","author":"Marais","year":"2014","journal-title":"Pigment Cell Melanoma Res"},{"key":"33","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1007\/s00262-017-1989-8","article-title":"The experience of immune checkpoint inhibitors in chinese patients with metastatic melanoma: a retrospective case series.","volume":"6","author":"Zhang","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"34","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation.","volume":"37","author":"Lebb\u00e9","year":"2015","journal-title":"N Engl J Med"},{"key":"35","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma.","volume":"37","author":"Neyns","year":"2015","journal-title":"N Engl J Med"},{"key":"36","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.","volume":"1","author":"Lorigan","year":"2015","journal-title":"Lancet Oncol"},{"key":"37","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1634\/theoncologist.2017-0133","article-title":"Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors.","volume":"2","author":"Geynisman","year":"2017","journal-title":"Oncologist"},{"key":"38","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1084\/jem.156.6.1755","article-title":"Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets.","volume":"15","author":"Old","year":"1982","journal-title":"J Exp Med"},{"key":"39","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.","volume":"37","author":"Arrieta","year":"2015","journal-title":"N Engl J Med"},{"key":"40","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","article-title":"Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination.","volume":"1","author":"Libenciuc","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer.","volume":"37","author":"Gainor","year":"2015","journal-title":"N Engl J Med"},{"key":"42","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.","volume":"38","author":"de Castro","year":"2016","journal-title":"Lancet"},{"key":"43","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer.","volume":"37","author":"Hotta","year":"2016","journal-title":"N Engl J Med"},{"key":"44","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00280-015-2873-x","article-title":"Phase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.","volume":"7","author":"Tokudome","year":"2015","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.103285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,2]],"date-time":"2020-09-02T20:26:22Z","timestamp":1599078382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.103285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,6,15]]}},"alternative-id":["103285","32516130"],"URL":"https:\/\/doi.org\/10.18632\/aging.103285","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]}}}